GSK (LON:GSK – Get Free Report)‘s stock had its “hold” rating restated by investment analysts at Deutsche Bank Aktiengesellschaft in a research report issued to clients and investors on Tuesday,Digital Look reports. They currently have a GBX 2,000 price target on the stock. Deutsche Bank Aktiengesellschaft’s price objective suggests a potential upside of 5.32% from the stock’s previous close.
GSK has been the topic of several other research reports. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 target price on shares of GSK in a research note on Wednesday, July 29th. Citigroup decreased their price objective on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, GSK currently has an average rating of “Hold” and a consensus target price of GBX 2,048.57.
Read Our Latest Stock Analysis on GSK
GSK Stock Down 0.5%
GSK (LON:GSK – Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. Equities analysts predict that GSK will post 175.980975 EPS for the current fiscal year.
Insider Buying and Selling at GSK
In other news, insider Jonathan Symonds bought 1,550 shares of the company’s stock in a transaction on Friday, June 19th. The shares were acquired at an average cost of GBX 1,935 per share, with a total value of £29,992.50. Also, insider Jeannie Lee purchased 802 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were purchased at an average price of GBX 5,069 per share, with a total value of £40,653.38. Over the last 90 days, insiders have bought 3,625 shares of company stock valued at $13,495,004. 0.20% of the stock is owned by company insiders.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Recommended Stories
- Five stocks we like better than GSK
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
